Renaissance Technologies LLC grew its position in Icon Plc (NASDAQ:ICLR) by 37.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,817,307 shares of the medical research company’s stock after buying an additional 495,247 shares during the period. Renaissance Technologies LLC owned approximately 3.36% of Icon worth $203,811,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in Icon in the 3rd quarter valued at $148,000. Financial Gravity Companies Inc. bought a new stake in Icon during the 4th quarter worth about $144,000. C M Bidwell & Associates Ltd. bought a new stake in Icon during the 4th quarter worth about $196,000. Advisor Partners LLC bought a new stake in Icon during the 4th quarter worth about $201,000. Finally, Dean Capital Investments Management LLC bought a new stake in Icon during the 4th quarter worth about $203,000. 90.50% of the stock is owned by institutional investors.
Icon Plc (NASDAQ:ICLR) traded up $0.31 during trading hours on Wednesday, reaching $121.72. 308,014 shares of the company’s stock were exchanged, compared to its average volume of 336,332. The firm has a market capitalization of $6,700.64, a PE ratio of 23.73, a price-to-earnings-growth ratio of 1.76 and a beta of 0.45. Icon Plc has a 1-year low of $76.46 and a 1-year high of $124.65. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.95 and a quick ratio of 1.95.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported $1.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.02. Icon had a net margin of 16.01% and a return on equity of 27.55%. The firm had revenue of $455.10 million during the quarter, compared to analysts’ expectations of $455.66 million. During the same period last year, the company earned $1.33 earnings per share. The business’s revenue was up 4.6% on a year-over-year basis. research analysts forecast that Icon Plc will post 6.02 EPS for the current year.
A number of brokerages have recently issued reports on ICLR. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub upgraded shares of Icon from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. KeyCorp restated a “buy” rating and set a $130.00 target price on shares of Icon in a research report on Thursday, January 11th. Mizuho set a $109.00 target price on shares of Icon and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, SunTrust Banks reiterated a “buy” rating and set a $133.00 price target on shares of Icon in a research report on Monday, January 22nd. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Icon has an average rating of “Buy” and an average target price of $126.00.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/14/icon-plc-iclr-shares-bought-by-renaissance-technologies-llc.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.